We started our journey to make a difference. To develop analytical and scientific products and services that would enable critical improvement in the analytical workflow to benefit our customers and partners. It was also an aspiration that we knew could lead to a profound impact on human well-being enabled by the delivery of precision products that protect the sample integrity and minimise result variation, leading to more informed decisions and treatments.
We welcome you as an investor and invite you to take a tour of the Trajan facilities around the world to meet some of our incredible team who, like us, are supporting science that benefits people.
Trajan Group Holdings released its 1H FY22 Results on Thursday 24 February. Trajan Managing Director and CEO Stephen Tomisich and Chief Financial Officer Alister Hodges hosted a webcast the same day, providing investors with an overview of activity in 1H FY22.
Trajan Group Holdings held its first Annual General Meeting (AGM) at 9am AEDT on Wednesday 24 November. Watch the full recording of Trajan's 2021 AGM, or CEO Stephen Tomisich and Chair John Eales' individual presentations, below.
Trajan Group Holdings released its FY21 Full Year Results on Wednesday 25 August. Trajan Managing Director and CEO Stephen Tomisich hosted a webcast the same day, providing investors with an overview of activity in FY21 and a look at what's next for the Company.
Trajan is a purpose-led Australian business that aims to enrich human well-being through the design, manufacture and supply of precision consumable products, devices and solutions used in the analysis of biological, food, water and other environmental samples.
Strong customer relationships: Long-term relationships with global ‘blue-chip’ customers including OEMs, pharmaceutical companies and contract research organisations.
Market leading innovator: Strong technical expertise and know-how of the manufacturing of precision analytical instruments and components. Portfolio of innovative technologies and devices to support the trend towards decentralised, personalised data-based healthcare.
High quality and experienced management team: Global management team led by founders, assembled to provide the human capital platform required to execute on growth strategy.
Global infrastructure: Manufacturing and distribution operations, systems and certifications designed for customer proximity with 5 sites across 3 continents.
Ready to scale: Deep technology commercialisation pipeline and globally identified acquisition targets provide significant upside potential to the existing and strong underlying consumable and components business.
Strong track record: 7 complementary acquisitions completed pre listing, all self funded through continued high financial performance.
If you can’t find what you’re looking for on our website we’re happy to answer any questions about our company and products. Please connect with us on email@example.com